RajatBannerjiMDPhD

PubMed

• Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relap...
  Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott, Se Jeong, Lauren Boucher, Namita T Gupta, Suraj Gupta, Christina Adler, Max S...> ;Journal for Immunotherapy of Cancer. 2024 Mar 21
• 1 citations
  Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.
  Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R ...> ;Blood. 2024 Jan 22
• 3 citations
  Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
  Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan, Chaitra Ujjani, Nnadozie Emechebe, Rajesh Kamalakar, Catherine C Coombs, Lori Leslie, Pau...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jul 1
• 3 citations
  Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Pha...
  Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, Ryan N Rys, Jason Oeh, Eva Lin, Tim Sterne-Weiler, Ellen Rei Ingalla, MaryAnn G...> ;American Journal of Hematology. 2023 Mar 1
• 67 citations
  Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
  Constantine S Tam, John N Allan, Tanya Siddiqi, Thomas J Kipps, Ryan Jacobs, Stephen Opat, Paul M Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jack...> ;Blood. 2022 Jun 2
• 61 citations
  Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymp...
  Rajat Bannerji, Jon E Arnason, Ranjana H Advani, Jennifer R Brown, John N Allan, Stephen M Ansell, Jeffrey A Barnes, Susan M O'Brien, Julio C Chávez, Johannes Duell, A...> ;The Lancet. Haematology. 2022 May 1
• 14 citations
  Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.
  Gregory, G., Kumar, S., Wang, D., Mahadevan, D., Walker, P., Wagner-Johnston, N., Escobar, C., Bannerji, R., Bhutani, D., Chang, J., Hernandez-Ilizaliturri, F., Klein,...> ;Blood Advances. 2022 Feb 22
• 4 citations
  Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory ...
  Anupama Doraiswamy, Mansi Shah, Rajat Bannerji> ;Current Hematologic Malignancy Reports. 2021 Feb 1
• 6 citations
  Impact of Insurance Status on Survival Outcomes in Adults With Acute Lymphoblastic Leukemia (ALL): A Single-center Experience.
  Rebecca Krakora, Weichung Shih, Pallvi Popli, Elan Gorshein, Gratian Salaru, Dirk F. Moore, Chunxia Chen, Kevin A. David, Rajat Bannerji> ;Clinical Lymphoma, Myeloma & Leukemia. 2019 Nov 13
• 18 citations
  Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials
  Susan O'Brien, Samantha Jaglowski, John C. Byrd, Rajat Bannerji, Kristie A. Blum, Christopher P. Fox, Richard R. Furman, Peter Hillmen, Thomas J. Kipps, Marco Montillo...> ;JAMA Oncology. 2018 May 1
• 36 citations
  Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced ...
  Monica M. Mita, Alain C. Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small, Ying Ming Jou, Paul Kirschmeier, Da Zhang, Yali Zhu, Paul Statkevich, K. K. Sankhala, J...> ;British Journal of Cancer. 2017 Aug 31
• 1 citations
  Influenza Adherence Tool Kit: Implementation and Evaluation Among Allogeneic Hematopoietic Transplantation Recipients
  Tracy Krimmel, Rajat Bannerji, Maribel Borysyuk, Susan M. Schneider> ;Clinical Journal of Oncology Nursing. 2017 Jun 1
• 4 citations
  Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy
  Daniel J. Medina, Kevin A. David, Yong Lin, Dale G. Schaar, Vimal Patel, Mecide Gharibo, Rajat Bannerji, Kelly Walton, Joseph Aisner, Arnold B. Rabson, Roger Strair> ;Leukemia & Lymphoma. 2017 May 4
• 87 citations
  Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
  Joseph M. Flynn, Jeffrey A. Jones, Amy J. Johnson, Leslie A. Andritsos, Kami J. Maddocks, Samantha Jaglowski, Joshua Hessler, Michael R. Grever, Eun Kyung Im, Honghong...> ;Leukemia. 2015 Feb 24
• 54 citations
  Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
  Chaoxin Hu, Tikva Dadon, Venugopal Chenna, Shinichi Yabuuchi, Rajat Bannerji, Robert Booher, Peter Strack, Nilofer A Azad, Barry D. Nelkin, Anirban Maitra> ;Molecular Cancer Therapeutics. 2015 Jul 1
• 105 citations
  Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
  Monica M. Mita, Anil A. Joy, Alain C. Mita, Kamalesh Kumar Sankhala, Ying Ming Jou, Da Zhang, Paul Statkevich, Yali Zhu, Siu Long Yao, Karen Small, Rajat Bannerji, Cha...> ;Clinical Breast Cancer. 2014 Jun 1
• 73 citations
  Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
  Joe Stephenson, John Nemunaitis, Anil A. Joy, Julie C. Martin, Ying-Ming Jou, Da Zhang, Paul Statkevich, Siu-Long Yao, Yali Zhu, Honghong Zhou, Karen Small, Rajat Bann...> ;Lung Cancer. 2014 Feb 1
• 96 citations
  A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
  John Nemunaitis, Karen Small, Paul Kirschmeier, Da Zhang, Yali Zhu, Ying-Ming Jou, Paul Statkevich, Siu-Long Yao, Rajat Bannerji> ;Journal of Translational Medicine. 2013 Oct 16
• 64 citations
  Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
  Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan Padmanabhan Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Yi...> ;Cancer Chemotherapy and Pharmacology. 2013 Aug 15
• 22 citations
  Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies
  Da Zhang, Monica M. Mita, Geoffrey I. Shapiro, Jennifer Poon, Karen Small, A. Tzontcheva, Bhavna Kantesaria, Yali Zhu, Rajat Bannerji, Paul Statkevich> ;Cancer Chemotherapy and Pharmacology. 2012 Oct 9
• 65 citations
  The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leuke...
  Amy J. Johnson, Yuh-Ying Yeh, Lisa L. Smith, Amy J. Wagner, Joshua Hessler, Sneha V. Gupta, Joseph M. Flynn, Jeffrey A. Jones, Xiaoli Zhang, Rajat Bannerji, Michael R....> ;Leukemia. 2012 May 30
• 93 citations
  Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
  Georg Feldmann, Anjali Mishra, Savita Bisht, Collins Karikari, Ignacio Garrido-Laguna, Zeshaan A. Rasheed, Niki A. Ottenhof, Tikva Dadon, Hector A Alvarez, Volker Fend...> ;Cancer Biology & Therapy. 2011 Oct 1
• Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL.
  Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E, Heerema NA, Poon J, Small KA, Jou Y, Zhang D, Statkevich P, Grever MR, Bannerji R, Byrd JC> ;J. Clin. Oncol.. 2011-05-20
• A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results.
  Mita MM, Mita AC, Moseley J, Poon J, Small KA, Jou Y, Kirschmeier P, Zhang D, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig S, Bannerji R, ...> ;J. Clin. Oncol.. 2011-05-20
• A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered ...
  Nemunaitis J, Saltzman M, Rosenberg MA, Khaira D, Small K, Kirschmeier P, Statkevich P, Abutarif M, Yao S, Bannerji R> ;J. Clin. Oncol.. 2009-05-20
• Join now to see all

Abstracts/Posters

• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Rajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Rajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Rajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018